Overview
What is Glomerular Disease Study And Trial Consortium?
The Glomerular Disease Study and Trial Consortium is a nonprofit organization dedicated to enhancing understanding, diagnosis, and treatment of kidney diseases. They accomplish this mission by developing and disseminating relevant scientific, clinical, and educational materials, organizing seminars, training sessions, and educational courses for medical professionals and the general public. The Consortium also supports patient registries, biomarker studies, and genomic research by providing necessary infrastructure. Additionally, they offer discounted tuition through the GlomCon Scholarships and extend membership to underserved areas. Their efforts aim to aid 246 fellows in the medical field, ultimately improving care for individuals suffering from kidney diseases.
Official website here: www.glomcon.org
Is Glomerular Disease Study And Trial Consortium legitimate?
Glomerular Disease Study And Trial Consortium is a legitimate nonprofit organization registered as a 501(c)(3) entity. Glomerular Disease Study And Trial Consortium submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
Official website here: www.glomcon.org
What is the mission statement of Glomerular Disease Study And Trial Consortium?
The Glomerular Disease Study and Trial Consortium works towards raising awareness, promoting diagnosis, and aiding patients with kidney diseases. It achieves this mission by producing educational materials, seminars, and training for medical professionals and the public. The consortium also offers support for patient registries, biomarker studies, and genomic research. In addition, they collaborate with other charitable organizations focused on rare kidney diseases to further their objectives.
Official website here: www.glomcon.org
Who is the CEO of Glomerular Disease Study And Trial Consortium?
Dr Ali Poyan Mehr is the Board Member of Glomerular Disease Study And Trial Consortium.
Official website here: www.glomcon.org
What is the revenue of Glomerular Disease Study And Trial Consortium?
Glomerular Disease Study And Trial Consortium's revenue in 2022 was $320,412.
Official website here: www.glomcon.org
Who are the executives of Glomerular Disease Study And Trial Consortium and what are their salaries?
There 32 volunteers at Glomerular Disease Study And Trial Consortium.
Here are 5 key members and their salaries:
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Official website here: www.glomcon.org
Where can I find the form 990 for Glomerular Disease Study And Trial Consortium?
Glomerular Disease Study And Trial Consortium's most recent form 990 was submitted in 2022 and can be accessed here.
Official website here: www.glomcon.org
Learn more at the official website: www.glomcon.org
Mission Statement of Glomerular Disease Study And Trial Consortium
The Glomerular Disease Study and Trial Consortium is an organization dedicated to raising awareness, promoting diagnosis, and offering assistance to individuals dealing with kidney diseases. To accomplish this mission, the consortium engages in various activities. Firstly, it creates and disseminates scientific, clinical, and educational materials, seminars, and training programs for medical professionals and the general public. This educational outreach aims to equip healthcare providers with the latest knowledge on kidney diseases and empower the public with essential information about the diseases and their treatments.
Secondly, the consortium provides infrastructure and support for patient registries, biomarker studies, and genomic research. Patient registries are essential tools for tracking the progression and outcomes of kidney diseases, while biomarker studies help identify potential indicators of these diseases. Genomic research, on the other hand, delves into the genetic components of kidney diseases, which can lead to the discovery of new treatments and preventative measures. By supporting these research initiatives, the consortium contributes to the advancement of kidney disease diagnosis and treatment.
Lastly, the Glomerular Disease Study and Trial Consortium collaborates with other similar charitable organizations. By working together, these organizations can pool their resources and expertise to address the challenges associated with rare kidney diseases more effectively. This collaborative approach ensures that the consortium remains at the forefront of the fight against kidney diseases, leveraging the collective strengths of multiple organizations to achieve its mission.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
The Glomerular Disease Study and Trial Consortium significantly advances the understanding and treatment of kidney diseases, particularly glomerular disorders. By raising awareness and promoting accurate diagnosis, it directly impacts patient outcomes. The consortium develops and distributes essential scientific and educational materials, enhancing the knowledge base for both healthcare professionals and the public.
Through seminars, training programs, and scholarships, the consortium equips medical professionals with the tools necessary to improve patient care. Its support for patient registries and biomarker studies fosters critical research that can lead to innovative treatment options. Collaborating with other organizations focused on rare kidney diseases amplifies these efforts, creating a broader impact within the medical community and among patients.
By focusing on areas in need, such as providing discounted tuition and targeted educational courses for fellows, the consortium helps cultivate a new generation of specialists in kidney health. The collective efforts of the Glomerular Disease Study and Trial Consortium contribute significantly to the landscape of kidney disease research and treatment, ultimately enhancing the quality of life for patients affected by these conditions.
This information is meant to be a general summary of Glomerular Disease Study And Trial Consortium. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Program Service Revenue: $165,375
- Gross Receipts: $320,412
Assets and Liabilities:
- Total Assets: $264,096
- Total Liabilities: $8,718
- Net Assets: $255,378
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
Fellowship Tuition
Revenue
$108,773
Kidney Pathology Tuition
Revenue
$36,570
Membership Dues & Assessments
Revenue
$20,032
Organization Details
Founding Year
2021
Phone
(203) 927-7987Principal Officer
Dr Ali Poyan Mehr
Main Address
667 Sequoia Valley Road, Mill Valley, CA, 94941
Website
www.glomcon.orgNTEE Category
Code: H20 - Medical research
If you are a representative of Glomerular Disease Study And Trial Consortium and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.